Pembrolizumab, an immunotherapeutic agent against the programmed cell death 1 (PD-1) receptor on T cells, is approved to treat metastatic cancers, particularly cutaneous melanoma. Activated PD-1 reduces T-cell responses against tumors; pembrolizumab blocks this receptor, enhancing T-cell response to tumors.1 Ocular adverse events associated with pembrolizumab treatment include uveitis and conjunctivitis.1 Uveitis has been documented in 1% of treated patients; most such cases have been classified as anterior uveitis.1 Herein, we describe bilateral birdshot-like chorioretinopathy after pembrolizumab immunotherapy in a patient with cutaneous melanoma metastases.
Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment. JAMA Ophthalmol. 2018;136(10):1205–1207. doi:10.1001/jamaophthalmol.2018.1851
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: